Close Menu

NEW YORK – Quidel has begun to brand itself as one of the few remaining pure play diagnostics companies at the point of care. The company has expanded its offerings in recent years to mitigate lumpiness from a business dominated by seasonal flu testing. It has nearly completed integration of the cardiac and toxicology business it acquired from Alere two years ago, for example, and has launched a new immunoassay analyzer while continuing to build up its molecular diagnostics business.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.